Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.

Kim TM, Jung SH, Baek IP, Lee SH, Choi YJ, Lee JY, Chung YJ, Lee SH.

J Pathol. 2014 Aug;233(4):425-35. doi: 10.1002/path.4380.

PMID:
24870262
2.

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.

Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, Grönberg H.

Eur Urol. 2013 Feb;63(2):347-53. doi: 10.1016/j.eururo.2012.03.050. Epub 2012 Mar 31.

PMID:
22502944
3.

Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.

Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, Kim TM, Lee SH.

J Pathol. 2017 Jan;241(1):57-66. doi: 10.1002/path.4819. Epub 2016 Nov 21.

PMID:
27741368
4.

Integrative molecular profiling of routine clinical prostate cancer specimens.

Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA.

Ann Oncol. 2015 Jun;26(6):1110-8. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.

5.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

6.

Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.

Kim TM, Jung SH, An CH, Lee SH, Baek IP, Kim MS, Park SW, Rhee JK, Lee SH, Chung YJ.

Clin Cancer Res. 2015 Oct 1;21(19):4461-72. doi: 10.1158/1078-0432.CCR-14-2413. Epub 2015 May 15.

7.

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD.

J Pathol. 2013 Dec;231(4):413-23. doi: 10.1002/path.4251.

PMID:
24037760
8.

Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.

9.

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton C.

Ann Oncol. 2017 Oct 1;28(10):2472-2480. doi: 10.1093/annonc/mdx355.

PMID:
28961847
10.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
11.

The genomic evolution of human prostate cancer.

Mitchell T, Neal DE.

Br J Cancer. 2015 Jul 14;113(2):193-8. doi: 10.1038/bjc.2015.234. Epub 2015 Jun 30. Review.

12.

Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5. doi: 10.1158/1055-9965.EPI-09-0772. Epub 2009 Oct 27.

13.

Screening of genetic and expression alterations of SRC1 gene in prostate cancer.

Mäki HE, Waltering KK, Wallén MJ, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T.

Prostate. 2006 Sep 15;66(13):1391-8.

PMID:
16894533
14.

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP.

J Pathol. 2013 Sep;231(1):21-34. doi: 10.1002/path.4230.

15.

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, Brooks JD.

Prostate. 2005 May 1;63(2):187-97.

PMID:
15486987
16.

p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.

Schlechte H, Lenk SV, Löning T, Schnorr D, Rudolph BD, Ditscherlein G, Loening SA.

Eur Urol. 1998;34(5):433-40.

PMID:
9803007
17.

The mitochondrial and autosomal mutation landscapes of prostate cancer.

Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikström P, Wiklund P, Wiklund F, Egevad L, Grönberg H.

Eur Urol. 2013 Apr;63(4):702-8. doi: 10.1016/j.eururo.2012.11.053. Epub 2012 Dec 5.

PMID:
23265383
18.

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S.

Nature. 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933.

19.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

20.

Many private mutations originate from the first few divisions of a human colorectal adenoma.

Kang H, Salomon MP, Sottoriva A, Zhao J, Toy M, Press MF, Curtis C, Marjoram P, Siegmund K, Shibata D.

J Pathol. 2015 Nov;237(3):355-62. doi: 10.1002/path.4581. Epub 2015 Aug 3.

Supplemental Content

Support Center